SA515360603B1 - بولي ببتيدات مثبتة لعامل نمو شبيه بالانسولين - Google Patents

بولي ببتيدات مثبتة لعامل نمو شبيه بالانسولين Download PDF

Info

Publication number
SA515360603B1
SA515360603B1 SA515360603A SA515360603A SA515360603B1 SA 515360603 B1 SA515360603 B1 SA 515360603B1 SA 515360603 A SA515360603 A SA 515360603A SA 515360603 A SA515360603 A SA 515360603A SA 515360603 B1 SA515360603 B1 SA 515360603B1
Authority
SA
Saudi Arabia
Prior art keywords
amino acid
replaced
igf
glutamine
sequence
Prior art date
Application number
SA515360603A
Other languages
Arabic (ar)
English (en)
Inventor
هوبر ثوماس
فورنارو مارا
زوريني ماورو
Original Assignee
نوفارتيس ايه جي
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50073229&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SA515360603(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by نوفارتيس ايه جي filed Critical نوفارتيس ايه جي
Publication of SA515360603B1 publication Critical patent/SA515360603B1/ar

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/02Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575Hormones
    • C07K14/65Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/30Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
SA515360603A 2012-12-18 2015-06-17 بولي ببتيدات مثبتة لعامل نمو شبيه بالانسولين SA515360603B1 (ar)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261738475P 2012-12-18 2012-12-18
PCT/IB2013/060985 WO2014097116A1 (en) 2012-12-18 2013-12-16 Stabilized insulin-like growth factor polypeptides

Publications (1)

Publication Number Publication Date
SA515360603B1 true SA515360603B1 (ar) 2020-07-26

Family

ID=50073229

Family Applications (1)

Application Number Title Priority Date Filing Date
SA515360603A SA515360603B1 (ar) 2012-12-18 2015-06-17 بولي ببتيدات مثبتة لعامل نمو شبيه بالانسولين

Country Status (36)

Country Link
US (1) US10167329B2 (cg-RX-API-DMAC7.html)
EP (2) EP3626735A1 (cg-RX-API-DMAC7.html)
JP (1) JP6499080B2 (cg-RX-API-DMAC7.html)
KR (1) KR102182523B1 (cg-RX-API-DMAC7.html)
CN (1) CN105121462B (cg-RX-API-DMAC7.html)
AP (1) AP2015008440A0 (cg-RX-API-DMAC7.html)
AU (1) AU2013365796B2 (cg-RX-API-DMAC7.html)
BR (1) BR112015013708B1 (cg-RX-API-DMAC7.html)
CA (1) CA2894976C (cg-RX-API-DMAC7.html)
CL (1) CL2015001708A1 (cg-RX-API-DMAC7.html)
CR (2) CR20200079A (cg-RX-API-DMAC7.html)
CU (1) CU24308B1 (cg-RX-API-DMAC7.html)
CY (1) CY1122309T1 (cg-RX-API-DMAC7.html)
DK (1) DK2935320T3 (cg-RX-API-DMAC7.html)
EA (1) EA034356B1 (cg-RX-API-DMAC7.html)
EC (1) ECSP15031046A (cg-RX-API-DMAC7.html)
ES (1) ES2756330T3 (cg-RX-API-DMAC7.html)
GT (1) GT201500168A (cg-RX-API-DMAC7.html)
HR (1) HRP20191965T1 (cg-RX-API-DMAC7.html)
HU (1) HUE047386T2 (cg-RX-API-DMAC7.html)
IL (1) IL239387A0 (cg-RX-API-DMAC7.html)
LT (1) LT2935320T (cg-RX-API-DMAC7.html)
MA (1) MA38153B1 (cg-RX-API-DMAC7.html)
MX (1) MX363021B (cg-RX-API-DMAC7.html)
MY (1) MY174820A (cg-RX-API-DMAC7.html)
NZ (1) NZ708091A (cg-RX-API-DMAC7.html)
PE (2) PE20200894A1 (cg-RX-API-DMAC7.html)
PH (1) PH12015501271A1 (cg-RX-API-DMAC7.html)
PL (1) PL2935320T3 (cg-RX-API-DMAC7.html)
PT (1) PT2935320T (cg-RX-API-DMAC7.html)
RS (1) RS59545B1 (cg-RX-API-DMAC7.html)
SA (1) SA515360603B1 (cg-RX-API-DMAC7.html)
SG (1) SG11201503782PA (cg-RX-API-DMAC7.html)
SI (1) SI2935320T1 (cg-RX-API-DMAC7.html)
TN (1) TN2015000182A1 (cg-RX-API-DMAC7.html)
WO (1) WO2014097116A1 (cg-RX-API-DMAC7.html)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3052123A1 (en) * 2013-10-02 2016-08-10 Novartis Ag Insulin-like growth factor mimetics for use in therapy
KR20180137487A (ko) * 2016-03-04 2018-12-27 샤이어 휴먼 지네틱 테라피즈 인크. 재조합 폴리스타틴-fc 융합 단백질 및 듀시엔형 근이영양증 치료에서의 용도
US10953074B2 (en) * 2017-01-08 2021-03-23 Richard D. Lippman Composition and method for improving sensorineural hearing
EP3569614A1 (en) 2018-05-18 2019-11-20 Julius-Maximilians-Universität Würzburg Compounds and methods for the immobilization of myostatin-inhibitors on the extracellular matrix by transglutaminase
EP3813861A4 (en) * 2018-06-27 2022-08-10 Juvena Therapeutics, Inc. HEPARIN-ASSOCIATED POLYPEPTIDES AND THEIR USES
CN109053875B (zh) * 2018-08-31 2021-06-29 重庆大学 突变型igf-1、重组质粒、重组蛋白及应用
RU2711111C1 (ru) * 2018-09-05 2020-01-15 Илья Владимирович Духовлинов Гибридный белок igf-1-long для лечения инсульта, нуклеиновая кислота, вектор, клетка, фармацевтическая композиция, способ лечения
CN110642937B (zh) * 2019-10-11 2021-04-06 南开大学 多肽衍生物、纳米纤维及其应用
JP2023512423A (ja) 2019-12-24 2023-03-27 ジュベナ・セラピューティクス・インコーポレイテッド 再生性ポリペプチドおよびその使用
CN117999278A (zh) 2021-06-21 2024-05-07 裘美娜治疗公司 再生性多肽及其用途
EP4652282A2 (en) * 2023-11-14 2025-11-26 Cavalry Biosciences, Inc. Compositions for targeting muscle cells and uses thereof

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4475196A (en) 1981-03-06 1984-10-02 Zor Clair G Instrument for locating faults in aircraft passenger reading light and attendant call control system
US4447233A (en) 1981-04-10 1984-05-08 Parker-Hannifin Corporation Medication infusion pump
US4439196A (en) 1982-03-18 1984-03-27 Merck & Co., Inc. Osmotic drug delivery system
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4447224A (en) 1982-09-20 1984-05-08 Infusaid Corporation Variable flow implantable infusion apparatus
US4487603A (en) 1982-11-26 1984-12-11 Cordis Corporation Implantable microinfusion pump system
US4486194A (en) 1983-06-08 1984-12-04 James Ferrara Therapeutic device for administering medicaments through the skin
US4596556A (en) 1985-03-25 1986-06-24 Bioject, Inc. Hypodermic injection apparatus
US5374548A (en) 1986-05-02 1994-12-20 Genentech, Inc. Methods and compositions for the attachment of proteins to liposomes using a glycophospholipid anchor
MX9203291A (es) 1985-06-26 1992-08-01 Liposome Co Inc Metodo para acoplamiento de liposomas.
DE3883899T3 (de) 1987-03-18 1999-04-22 Sb2, Inc., Danville, Calif. Geänderte antikörper.
US4941880A (en) 1987-06-19 1990-07-17 Bioject, Inc. Pre-filled ampule and non-invasive hypodermic injection device assembly
US4790824A (en) 1987-06-19 1988-12-13 Bioject, Inc. Non-invasive hypodermic injection device
US5108921A (en) 1989-04-03 1992-04-28 Purdue Research Foundation Method for enhanced transmembrane transport of exogenous molecules
US5064413A (en) 1989-11-09 1991-11-12 Bioject, Inc. Needleless hypodermic injection device
US5312335A (en) 1989-11-09 1994-05-17 Bioject Inc. Needleless hypodermic injection device
US5383851A (en) 1992-07-24 1995-01-24 Bioject Inc. Needleless hypodermic injection device
WO2000040612A1 (en) * 1999-01-06 2000-07-13 Genentech, Inc. Insulin-like growth factor (igf) i mutant variants
WO2000040613A1 (en) 1999-01-06 2000-07-13 Genentech, Inc. Insulin-like growth factor (igf) i mutant variants
US7083970B2 (en) 2001-04-19 2006-08-01 The Scripps Research Institute Methods and compositions for the production of orthogonal tRNA-aminoacyl tRNA synthetase pairs
US7355018B2 (en) 2003-09-30 2008-04-08 Regeneron Pharmaceuticals, Inc. Modified IGF1 polypeptides with increased stability and potency
EP1674113A1 (en) 2004-12-22 2006-06-28 F. Hoffmann-La Roche Ag Conjugates of insulin-like growth factor-1 (IGF-1) and poly(ethylene glycol)
CA2594023C (en) * 2005-01-07 2015-07-14 Regeneron Pharmaceuticals, Inc. Igf-i fusion polypeptides and therapeutic uses thereof
US7521211B2 (en) * 2005-04-05 2009-04-21 Regeneron Pharmaceuticals, Inc IGF-1 and IGF-2 chimeric polypeptides and therapeutic uses thereof
CN101466398A (zh) * 2006-06-09 2009-06-24 诺瓦提斯公司 稳定的胰岛素样生长因子多肽
MX2008015726A (es) 2006-06-09 2008-12-19 Novartis Ag Polipeptidos de factor de crecimiento de tipo insulina estabilizada.
ES2784926T3 (es) 2007-12-21 2020-10-02 Novartis Ag Vector de expresión de mamífero
HUE035240T2 (hu) 2009-04-27 2018-05-02 Novartis Ag Készítmények és eljárások az izomerõ növelésére
WO2011011073A1 (en) * 2009-07-22 2011-01-27 Ipsen Pharma S.A.S. Site-specific pegylated or site-specific lipidated igf-1 and analogues of igf-1
WO2011011071A2 (en) 2009-07-22 2011-01-27 Ipsen Pharma S.A.S. Analogues of insulin-like growth factor-1 (igf-1)
US10030063B2 (en) 2012-12-18 2018-07-24 Novartis Ag Production of therapeutic proteins in genetically modified mammalian cells
EP3052123A1 (en) 2013-10-02 2016-08-10 Novartis Ag Insulin-like growth factor mimetics for use in therapy
UY35874A (es) 2013-12-12 2015-07-31 Novartis Ag Un proceso para la preparación de una composición de proteínas pegiladas

Also Published As

Publication number Publication date
US10167329B2 (en) 2019-01-01
CN105121462A (zh) 2015-12-02
PT2935320T (pt) 2019-11-15
EP2935320B1 (en) 2019-08-21
BR112015013708B1 (pt) 2022-10-18
PE20151612A1 (es) 2015-11-19
CN105121462B (zh) 2019-08-02
MY174820A (en) 2020-05-17
RS59545B1 (sr) 2019-12-31
CA2894976C (en) 2022-10-04
PE20200894A1 (es) 2020-09-08
WO2014097116A1 (en) 2014-06-26
AU2013365796B2 (en) 2017-03-30
ES2756330T3 (es) 2020-04-27
EP2935320A1 (en) 2015-10-28
EA034356B1 (ru) 2020-01-30
CU20150064A7 (es) 2016-02-29
CL2015001708A1 (es) 2015-08-28
HUE047386T2 (hu) 2020-04-28
NZ708091A (en) 2018-03-23
EP3626735A1 (en) 2020-03-25
KR102182523B1 (ko) 2020-11-25
SG11201503782PA (en) 2015-06-29
DK2935320T3 (da) 2019-11-18
MA38153B1 (fr) 2018-06-29
PL2935320T3 (pl) 2020-03-31
SI2935320T1 (sl) 2019-12-31
BR112015013708A2 (pt) 2017-11-14
CR20150324A (es) 2015-08-10
PH12015501271B1 (en) 2015-08-24
MA38153A1 (fr) 2016-06-30
AU2013365796A1 (en) 2015-05-28
CY1122309T1 (el) 2021-01-27
KR20150095879A (ko) 2015-08-21
EA201591165A1 (ru) 2015-11-30
GT201500168A (es) 2016-01-21
AP2015008440A0 (en) 2015-05-31
JP2016501025A (ja) 2016-01-18
CR20200079A (es) 2020-03-21
CA2894976A1 (en) 2014-06-26
ECSP15031046A (es) 2019-03-29
TN2015000182A1 (en) 2016-10-03
MX2015007932A (es) 2015-10-05
PH12015501271A1 (en) 2015-08-24
HRP20191965T1 (hr) 2020-01-24
MX363021B (es) 2019-03-05
IL239387A0 (en) 2015-07-30
JP6499080B2 (ja) 2019-04-10
CU24308B1 (es) 2018-01-10
US20150329614A1 (en) 2015-11-19
LT2935320T (lt) 2019-11-11
HK1212712A1 (en) 2016-06-17

Similar Documents

Publication Publication Date Title
SA515360603B1 (ar) بولي ببتيدات مثبتة لعامل نمو شبيه بالانسولين
JP7427046B2 (ja) Bdnfを含む融合蛋白質
US20230346966A1 (en) Muscle-targeting complexes and uses thereof in treating muscle atrophy
CN107835820B (zh) 识别癌症特异性IL13Rα2的CAR T细胞
KR20190099470A (ko) 혈액뇌관문을 통과하는 신규한 항인간 트랜스페린 수용체 항체
TW202035440A (zh) 新穎合理設計的蛋白質組合物
TW200808830A (en) Mutant polypeptide having effector function
EP4640708A1 (en) Novel anti-gprc5d antibody
EP4082572A1 (en) Anti-ctla-4 monoclonal antibody, preparation method therefor, and application thereof
US20250129170A1 (en) Epo receptor agonists and antagonists
EP4613771A1 (en) Chimeric antigen receptor with increased affinity for mesothelin and use thereof
US20260007749A1 (en) Chimeric antigen receptor with increased affinity for mesothelin and use thereof
US11883433B1 (en) Chimeric antigen receptor comprising anti-mesothelin scFv, and use thereof
EP4613774A1 (en) Single domain antibody targeting human ror1
CA3272347A1 (en) Chimeric antigen receptor with increased affinity for mesothelin and use thereof
HK1212712B (en) Stabilized insulin-like growth factor polypeptides
CN118139892A (zh) 一种三靶点抗肿瘤药物、其制备方法及其应用